TICKERNERD
Menu
SGHTSGHTHealthcare · Medical Devices

SGHT Stock Forecast: Sight Sciences, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$8.47
0.00% on the day

The 7 Wall Street analysts covering Sight Sciences, Inc. hold a median 12-month price target of $9 — +6.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 90 of 100 as at 8 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$471.6M
Ticker Nerd rank
90 / 100
Median analyst target
$9.00
Analysts covering
7
Revenue$23.4M+19.5% y/y
Operating income−$3.9M
Net income−$4.4M
Free cash flow−$5.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−6.2%
1M
+4.6%
YTD
+6.8%
1Y
+144.1%
From 52W high
−9.5%
From 52W low
+164.7%
$3.20
$9.36
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SGHT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Sight Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
90 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
97
Revisions
96
Growth
93
Accruals
68
Quality
67
Size
54
Value
51
Issuance
30
Volatility
13

Momentum (97): The shares have been drifting up relative to others.

Volatility (13): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SGHT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SGHT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00$12.00Jan 26Apr 26Jul 26Oct 26SGHTHigh $12.00Median $9.00Low $8.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
5 Buy2 Hold0 Sell
Low $8.00Median $9.00High $12.00

The green dot is the last close — the median target sits +6.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
6 Aug 2026UBSMaintainsBuy$7.00 → $8.00
28 July 2026UBSAssumesBuy$11 → $7.00
8 July 2026CitigroupMaintainsNeutral$5.15 → $6.00
8 July 2026CitigroupMaintainsNeutral—
28 May 2026CitigroupMaintainsNeutral—
6 Mar 2026CitigroupMaintainsNeutral—
6 Mar 2026UBSMaintainsBuy—
2 Mar 2026StifelMaintainsBuy—
5 Jan 2026Piper SandlerUpgradeOverweight—
23 Dec 2025UBSMaintainsBuy—
11 Dec 2025CitigroupMaintainsNeutral—
10 Dec 2025Lake StreetMaintainsBuy—
2 Dec 2025Morgan StanleyMaintainsEqual-Weight—
10 Nov 2025Morgan StanleyMaintainsEqual-Weight—
7 Nov 2025Piper SandlerMaintainsNeutral—
21 Oct 2025Lake StreetMaintainsBuy—
7 Oct 2025CitigroupMaintainsNeutral—
28 Aug 2025NeedhamReiteratesHold—
21 Aug 2025CitigroupMaintainsNeutral—
8 Aug 2025Lake StreetUpgradeBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SGHT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

SGHT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Sight Sciences, Inc. returned +144.1% against +16.2% for the S&P 500, dividends included.

SGHT vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300Jan 26Apr 26Jul 26Oct 26SGHTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SGHT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
0
Fundamentals

Sight Sciences, Inc. (SGHT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−11.5×

Cheaper than 94% of US stocks

Price / sales
5.7×

Cheaper than 22% of US stocks

Price / book
8.9×

Cheaper than 11% of US stocks

EV / EBITDA
−22.5×

Cheaper than 90% of US stocks

Growth & margins
Revenue growth (YoY)
19.5%

Higher than 69% of US stocks

Earnings growth (YoY)
19.5%

Higher than 58% of US stocks

Gross margin
91.4%

Higher than 97% of US stocks

Operating margin
−16.6%

Higher than 22% of US stocks

Net margin
−35.7%

Higher than 12% of US stocks

Returns & dividend
Return on equity
−48.4%

Higher than 22% of US stocks

Return on assets
−10.8%

Higher than 26% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Sight Sciences, Inc. (SGHT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Sight Sciences, Inc. has a market value of $471.6M and an enterprise value of $433.8M.

  • Revenue in the twelve months to 30 June 2026: $83.4M. The latest quarter grew 19.5% year on year.

  • Net income over the same four quarters: −$29.8M, a −35.7% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.56.

  • Free cash flow in the twelve months to 30 June 2026: −$23.3M.

  • Shares outstanding: 54.7M.

  • Trailing P/E: −11.5×; forward P/E: −19.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Sight Sciences, Inc. employs 186 people — $448K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

SGHT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
SGHTSight Sciences, Inc.$471.6M
90
SENSSenseonics Holdings, Inc.$470.9M
31
MASS908 Devices, Inc.$473.9M
86
CERSCerus Corp.$438.0M
91
TCMDTactile Systems Technology, Inc.$498.9M
98
NPCENeuroPace, Inc.$417.1M
93
RCELAVITA Medical, Inc.$412.3M
73

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Sight Sciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SGHT news & analysis

Sight Sciences to Debut the OMNI Ultra® Surgical System, the Latest Technology Advancement from the Pioneers of Ab Interno Canaloplasty, at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting

GlobeNewsWire · 1 Oct 2026positive

Sight Sciences announced the commercial availability of the OMNI Ultra Surgical System, an expansion of its ab interno canaloplasty platform, and will debut the technology at the 2026 American Academy of Ophthalmology annual meeting in New Orleans, October 9-12.

Why it matters — The commercial launch and featured debut of a new technology at a major industry conference signals continued expansion of Sight Sciences' core surgical platform, which is relevant to SGHT watchers.

Sight Sciences, Inc. (SGHT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · 15 Sept 2026neutral

Sight Sciences, Inc. presented at the Morgan Stanley 24th Annual Global Healthcare Conference, with a transcript of the presentation made available via Seeking Alpha. The company's leadership participated in the conference as part of its investor-relations activities.

Why it matters — SGHT watchers would care because a conference presentation provides direct insight into the company's current strategic messaging and business outlook as conveyed to the investment community.

TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease

GlobeNewsWire · 19 Aug 2026positive

Sight Sciences announced that, effective August 18, 2026, the FDA updated the Indications for Use for its TearCare System, making it the first and only meibomian gland dysfunction (MGD) treatment indicated to improve meibomian gland function in patients with evaporative dry eye disease.

Why it matters — This regulatory update gives Sight Sciences' TearCare a differentiated, first-of-its-kind labeling claim that may strengthen its market position in the MGD treatment space.

Sight Sciences, Inc. (SGHT) Q2 2026 Earnings Call Transcript

Seeking Alpha · 6 Aug 2026neutral

Sight Sciences, Inc. published its Q2 2026 earnings call transcript via Seeking Alpha, covering the company's second-quarter results and management's remarks on its business performance during the call.

Why it matters — A SGHT watcher would care because the transcript offers management's own commentary on the company's Q2 2026 performance and outlook in its own words.

FAQ

Frequently asked questions about SGHT stock

What is the SGHT stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Sight Sciences, Inc. have a median 12-month price target of $9, with estimates ranging from $8 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SGHT stock a buy right now?

Of the 7 analysts covering Sight Sciences, Inc., 5 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Sight Sciences, Inc. 90 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SGHT?

As at 8 Oct 2026, Sight Sciences, Inc. ranks 90 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (97 of 100).

Will SGHT stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +6.3% from the last close, and Ticker Nerd's factor model ranks Sight Sciences, Inc. 90 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SGHT stock forecast for 2030?

No analyst covering Sight Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SGHT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $12 over the next 12 months.

How has SGHT stock performed over the past year?

Sight Sciences, Inc. returned +144.1% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Sight Sciences, Inc. do?

Sight Sciences, Inc. is an ophthalmic medical device company focused on developing and commercializing interventional technologies for glaucoma and dry eye disease.

What is the latest news on SGHT?

The most recent item we track (GlobeNewsWire, 1 Oct 2026): "Sight Sciences to Debut the OMNI Ultra® Surgical System, the Latest Technology Advancement from the Pioneers of Ab Interno Canaloplasty, at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting". Sight Sciences announced the commercial availability of the OMNI Ultra Surgical System, an expansion of its ab interno canaloplasty platform, and will debut the technology at the 2026 American Academy of Ophthalmology annual meeting in New Orleans, October 9-12.

Company

About Sight Sciences, Inc.

Sight Sciences, Inc. is an ophthalmic medical device company focused on developing and commercializing interventional technologies for glaucoma and dry eye disease. Its current product portfolio includes the OMNI Surgical System family for minimally invasive glaucoma procedures, the SION Surgical Instrument for trabecular meshwork excision, and the TearCare System for treating evaporative dry eye associated with meibomian gland dysfunction. The company serves eyecare providers, including ophthalmologists and optometrists, by offering tools designed to address key causes of intraocular pressure buildup and tear-film dysfunction. Sight Sciences operates through its Surgical Glaucoma and Dry Eye segments, positioning its products across procedural eyecare settings where device-based treatment options are used to support patient care. Headquartered in Menlo Park, California, Sight Sciences plays a focused role in the medical technology market by supplying specialized devices for prevalent eye conditions.

CEO Mr. Paul Badawi · 186 employees · United States · https://www.sightsciences.com